이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biophytis 미래 성장

Future 기준 확인 0/6

Biophytis (는) 각각 연간 18.5% 및 103.6% 수익과 수익이 증가할 것으로 예상됩니다.

주요 정보

18.5%

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	31.3%
매출 성장률	103.6%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	15 May 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:6XB3 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	19	-8	N/A	N/A	1
12/31/2025	5	-17	N/A	N/A	1
12/31/2024	N/A	-20	N/A	N/A	1
12/31/2023	N/A	-17	-13	-13	N/A
9/30/2023	N/A	-18	-15	-15	N/A
6/30/2023	N/A	-20	-17	-17	N/A
3/31/2023	N/A	-22	-18	-18	N/A
12/31/2022	N/A	-24	-19	-19	N/A
9/30/2022	N/A	-27	-20	-20	N/A
6/30/2022	N/A	-30	-21	-21	N/A
3/31/2022	N/A	-31	-23	-22	N/A
12/31/2021	N/A	-31	-24	-24	N/A
9/30/2021	N/A	-28	-24	-24	N/A
6/30/2021	N/A	-25	-24	-23	N/A
3/31/2021	N/A	-25	-17	-17	N/A
12/31/2020	N/A	-26	-10	-10	N/A
9/30/2020	N/A	-24	-7	-7	N/A
6/30/2020	N/A	-22	-4	-4	N/A
3/31/2020	N/A	-22	-10	-10	N/A
12/31/2019	N/A	-19	-15	-15	N/A
9/30/2019	N/A	-19	-16	-16	N/A
6/30/2019	N/A	-18	-17	-16	N/A
3/31/2019	N/A	-15	-14	-14	N/A
12/31/2018	N/A	-14	-12	-12	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-12	-10	-10	N/A
3/31/2018	N/A	-12	-10	-10	N/A
12/31/2017	N/A	-11	-9	-9	N/A
9/30/2017	N/A	-10	N/A	-9	N/A
6/30/2017	N/A	-9	N/A	-9	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-7	N/A
9/30/2016	N/A	-8	N/A	-6	N/A
6/30/2016	N/A	-7	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-4	N/A
12/31/2015	N/A	-5	N/A	-3	N/A
9/30/2015	N/A	-4	N/A	-2	N/A
6/30/2015	N/A	-2	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-1	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 6XB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 6XB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 6XB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 6XB3 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: 6XB3 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 6XB3 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Biophytis 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Independent Director Jean Franchi has left the company

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

New 90-day high: €1.67

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Biophytis SA Receives DMC Recommendation for Starting Recruitment for Part 2 of Its Phase 2-3 Cova Study in COVID-19

New 90-day high: €1.25

New 90-day high: €0.73

New 90-day high: €0.72

Biophytis Enrolls First Patient in Brazil in COVA, A Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

New 90-day low: €0.40

New 90-day low: €0.51

New 90-day low - €0.63

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견